Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Inventiva (0RNK – Research Report). The associated price target is €10.00.
Ritu Baral has given her Buy rating due to a combination of factors related to Inventiva’s ongoing clinical developments and financial positioning. The completion of enrollment in the Phase 3 NATIV3 MASH trial is a significant milestone, with topline data expected in the second half of 2026. This trial, which includes a substantial number of participants, is strategically designed to assess the efficacy of lanifibranor in patients with F2/F3 MASH, providing a potential pathway for accelerated approval.
Additionally, Inventiva’s financial outlook supports this positive rating. The company reported a cash position of €96.6 million at the end of FY24, with an additional €116 million expected from a structured financing deal in the second quarter of 2025. This financial runway is projected to extend operational expenses until the third quarter of 2026. The strategic focus on the lanifibranor program, including a reduction in workforce and a pause in preclinical research, further underscores the company’s commitment to advancing this pivotal trial.
Baral covers the Healthcare sector, focusing on stocks such as Insmed, Alnylam Pharma, and Sarepta Therapeutics. According to TipRanks, Baral has an average return of 2.9% and a 39.36% success rate on recommended stocks.